It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
KAYS’s FA Score shows that 1 FA rating(s) are green whileKMDA’s FA Score has 0 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
KAYS’s TA Score shows that 2 TA indicator(s) are bullish while KMDA’s TA Score has 4 bullish TA indicator(s).
KAYS (@Pharmaceuticals: Other) experienced а 0.00% price change this week, while KMDA (@Pharmaceuticals: Other) price change was -4.45% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +0.99%. For the same industry, the average monthly price growth was +1.98%, and the average quarterly price growth was -8.51%.
KAYS is expected to report earnings on Apr 27, 2023.
KMDA is expected to report earnings on Feb 12, 2025.
Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
KAYS | KMDA | KAYS / KMDA | |
Capitalization | 1.24M | 306M | 0% |
EBITDA | -1.42M | 22.4M | -6% |
Gain YTD | -26.366 | -5.229 | 504% |
P/E Ratio | 0.70 | 37.43 | 2% |
Revenue | 545K | 143M | 0% |
Total Cash | 30.5K | 55.6M | 0% |
Total Debt | 7.66M | 8.82M | 87% |
KAYS | KMDA | ||
---|---|---|---|
OUTLOOK RATING 1..100 | 72 | 79 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 50 Fair valued | 67 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 100 | 79 | |
PRICE GROWTH RATING 1..100 | 82 | 50 | |
P/E GROWTH RATING 1..100 | 1 | 96 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
KAYS's Valuation (50) in the null industry is in the same range as KMDA (67) in the Biotechnology industry. This means that KAYS’s stock grew similarly to KMDA’s over the last 12 months.
KAYS's Profit vs Risk Rating (100) in the null industry is in the same range as KMDA (100) in the Biotechnology industry. This means that KAYS’s stock grew similarly to KMDA’s over the last 12 months.
KMDA's SMR Rating (79) in the Biotechnology industry is in the same range as KAYS (100) in the null industry. This means that KMDA’s stock grew similarly to KAYS’s over the last 12 months.
KMDA's Price Growth Rating (50) in the Biotechnology industry is in the same range as KAYS (82) in the null industry. This means that KMDA’s stock grew similarly to KAYS’s over the last 12 months.
KAYS's P/E Growth Rating (1) in the null industry is significantly better than the same rating for KMDA (96) in the Biotechnology industry. This means that KAYS’s stock grew significantly faster than KMDA’s over the last 12 months.
KAYS | KMDA | |
---|---|---|
RSI ODDS (%) | N/A | 4 days ago83% |
Stochastic ODDS (%) | 1 day ago90% | 1 day ago73% |
Momentum ODDS (%) | 1 day ago90% | 1 day ago66% |
MACD ODDS (%) | 1 day ago88% | 1 day ago74% |
TrendWeek ODDS (%) | 1 day ago80% | 1 day ago69% |
TrendMonth ODDS (%) | 1 day ago87% | 1 day ago69% |
Advances ODDS (%) | N/A | 11 days ago68% |
Declines ODDS (%) | 15 days ago82% | 3 days ago69% |
BollingerBands ODDS (%) | 1 day ago90% | 1 day ago63% |
Aroon ODDS (%) | 1 day ago90% | 1 day ago54% |
A.I.dvisor tells us that KAYS and KMDA have been poorly correlated (+21% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that KAYS and KMDA's prices will move in lockstep.
Ticker / NAME | Correlation To KAYS | 1D Price Change % | ||
---|---|---|---|---|
KAYS | 100% | -2.21% | ||
KMDA - KAYS | 21% Poorly correlated | +0.87% | ||
UPC - KAYS | 8% Poorly correlated | -0.79% | ||
SHIEF - KAYS | 4% Poorly correlated | N/A | ||
TRUFF - KAYS | 4% Poorly correlated | -2.07% | ||
AYRWF - KAYS | 3% Poorly correlated | -4.67% | ||
More |
A.I.dvisor tells us that KMDA and NXSCF have been poorly correlated (+27% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that KMDA and NXSCF's prices will move in lockstep.
Ticker / NAME | Correlation To KMDA | 1D Price Change % | ||
---|---|---|---|---|
KMDA | 100% | +0.87% | ||
NXSCF - KMDA | 27% Poorly correlated | N/A | ||
SGIOY - KMDA | 27% Poorly correlated | -1.29% | ||
INCR - KMDA | 27% Poorly correlated | -1.05% | ||
ACET - KMDA | 22% Poorly correlated | -6.28% | ||
RDY - KMDA | 22% Poorly correlated | +0.48% | ||
More |